{"success":true,"data":{"pressRelease":{"id":"45670","rtpr_id":"nGNXb5fZcj","ticker":"APGE","exchange":"NASDAQ","all_tickers":["APGE"],"title":"Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026","author":"Globe Newswire","published_at":"2026-05-26T20:01:00.104Z","article_body":"SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee\nTherapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company\nadvancing optimized, novel biologics with potential for best-in-class profiles\nin the largest inflammatory and immunology (I&I) markets, today announced it\nwill report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on\nWednesday, May 27, 2026. Following the announcement, the company will host a\nconference call and webcast at 8:00 a.m. ET to discuss the results.\n\nWebcast Details\n\nApogee Therapeutics’ live webcast of the Phase 2 APEX Part B results will\nbegin on Wednesday, May 27 at 8:00 a.m. ET. The live webcast can be accessed\nvia this link\n(https://www.globenewswire.com/Tracker?data=VcD2nckL7oyIPX4dM-Rz3FAmtSY-GjLkMm7qSYPqBVpaF4IadF_YbF8nKJowjsNYm_O4C_zPQ8sZ77vo7JWh-1gZEIqOlNiuW4XF3OLyMmU=)\nor the Investors section on the Company’s website at\nhttps://investors.apogeetherapeutics.com/news-events/events. A replay of the\nwebcast will be available following the call.\n\nAbout Apogee\n\nApogee Therapeutics is a clinical-stage biotechnology company advancing novel\nbiologics with potential for differentiated efficacy and dosing in the largest\nI&I markets, including for the treatment of AD, asthma, EoE, Chronic\nObstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s\nantibody programs are designed to overcome limitations of existing therapies\nby targeting well-established mechanisms of action and incorporating advanced\nantibody engineering to optimize half-life and other properties. Zumilokibart,\nthe company’s most advanced program, is being initially developed for the\ntreatment of AD, which is the largest and one of the least penetrated I&I\nmarkets, as well as asthma and EoE. With four validated targets in its\nportfolio, Apogee is seeking to achieve best-in-class efficacy and dosing\nthrough monotherapies and combinations of its novel antibodies. Based on a\nbroad pipeline and depth of expertise, the company believes it can deliver\nvalue and meaningful benefit to patients underserved by today’s standard of\ncare. For more information, please visit https://apogeetherapeutics.com.\n\nInvestor Contact:\nNoel Kurdi\nVP, Investor Relations\nApogee Therapeutics, Inc.\nNoel.Kurdi@apogeetherapeutics.com\n\nMedia Contact:\nDan Budwick\n1AB Media\ndan@1abmedia.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXb5fZcj","title":"Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026","author":"Globe Newswire","ticker":"APGE","created":"2026-05-26T20:01:00.104Z","tickers":["APGE"],"exchange":"NASDAQ","article_body":"SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee\nTherapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company\nadvancing optimized, novel biologics with potential for best-in-class profiles\nin the largest inflammatory and immunology (I&I) markets, today announced it\nwill report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on\nWednesday, May 27, 2026. Following the announcement, the company will host a\nconference call and webcast at 8:00 a.m. ET to discuss the results.\n\nWebcast Details\n\nApogee Therapeutics’ live webcast of the Phase 2 APEX Part B results will\nbegin on Wednesday, May 27 at 8:00 a.m. ET. The live webcast can be accessed\nvia this link\n(https://www.globenewswire.com/Tracker?data=VcD2nckL7oyIPX4dM-Rz3FAmtSY-GjLkMm7qSYPqBVpaF4IadF_YbF8nKJowjsNYm_O4C_zPQ8sZ77vo7JWh-1gZEIqOlNiuW4XF3OLyMmU=)\nor the Investors section on the Company’s website at\nhttps://investors.apogeetherapeutics.com/news-events/events. A replay of the\nwebcast will be available following the call.\n\nAbout Apogee\n\nApogee Therapeutics is a clinical-stage biotechnology company advancing novel\nbiologics with potential for differentiated efficacy and dosing in the largest\nI&I markets, including for the treatment of AD, asthma, EoE, Chronic\nObstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s\nantibody programs are designed to overcome limitations of existing therapies\nby targeting well-established mechanisms of action and incorporating advanced\nantibody engineering to optimize half-life and other properties. Zumilokibart,\nthe company’s most advanced program, is being initially developed for the\ntreatment of AD, which is the largest and one of the least penetrated I&I\nmarkets, as well as asthma and EoE. With four validated targets in its\nportfolio, Apogee is seeking to achieve best-in-class efficacy and dosing\nthrough monotherapies and combinations of its novel antibodies. Based on a\nbroad pipeline and depth of expertise, the company believes it can deliver\nvalue and meaningful benefit to patients underserved by today’s standard of\ncare. For more information, please visit https://apogeetherapeutics.com.\n\nInvestor Contact:\nNoel Kurdi\nVP, Investor Relations\nApogee Therapeutics, Inc.\nNoel.Kurdi@apogeetherapeutics.com\n\nMedia Contact:\nDan Budwick\n1AB Media\ndan@1abmedia.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-26T20:01:00.151146091Z","server_sent_at_ms":1779825660151},"received_at":"2026-05-26T20:01:00.229Z","source_url":null},"analysis":{"id":"35104","press_release_id":"45670","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Apogee Therapeutics will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on May 27, 2026.\n\nThe data pertains to patients with moderate-to-severe atopic dermatitis.\n\nA conference call and webcast will follow the announcement at 8:00 a.m. ET to discuss the results.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Pre-announcement for Phase 2 data readout tomorrow; wait for actual results before posting."},"keyFigures":{"drugName":"zumilokibart","phaseOfTrial":"Phase 2","customDimensions":{"trial_name":"APEX","trial_part":"Part B","duration_weeks":16}},"quotedText":"Apogee Therapeutics... today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026.","namedEntities":{"people":[{"name":"Noel Kurdi","role":"VP, Investor Relations"},{"name":"Dan Budwick","role":"Media Contact"}],"products":["zumilokibart"],"companies":[{"name":"Apogee Therapeutics, Inc.","ticker":"APGE"},{"name":"1AB Media","relationship":"PR agency"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"This is a pre-announcement for Phase 2 data readout. While binary in nature, the results are not yet disclosed, so the impact is limited to scheduling awareness. The actual data release tomorrow will determine the true material impact."},"tickerRelevance":{"others":[],"primary":"APGE"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"pre-announcement","sectorWeight":"high","marketCapAdjustment":"neutral"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"neutral","material_impact_score":3,"narrative":"Apogee Therapeutics will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on May 27, 2026.\n\nThe data pertains to patients with moderate-to-severe atopic dermatitis.\n\nA conference call and webcast will follow the announcement at 8:00 a.m. ET to discuss the results.","key_figures":{"drugName":"zumilokibart","phaseOfTrial":"Phase 2","customDimensions":{"trial_name":"APEX","trial_part":"Part B","duration_weeks":16}},"named_entities":{"people":[{"name":"Noel Kurdi","role":"VP, Investor Relations"},{"name":"Dan Budwick","role":"Media Contact"}],"products":["zumilokibart"],"companies":[{"name":"Apogee Therapeutics, Inc.","ticker":"APGE"},{"name":"1AB Media","relationship":"PR agency"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-26T20:01:18.373Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"pre-announcement","sectorWeight":"high","marketCapAdjustment":"neutral"}},"durationMs":17759,"modelName":"george-droid-qwen-72b"}}